Incremental costs, effects and cost-effectiveness ratios of the infliximab versus the conventional treatment strategy
| Perspective/method | n | Incremental cost (€) | Incremental effect (QALY) | ICER (€ per QALY) | % Cost-effective at willingness-to-pay per QALY | ||
|---|---|---|---|---|---|---|---|
| €50 000 (%) | €100 000 (%) | €1 000 000 (%) | |||||
| Societal perspective | |||||||
| Overall (main analysis) | 258 | 20 916 | 0.009 | 2 404 197 | 0 | 0 | 38 |
| Sensitivity analysis | |||||||
| Friction cost method | 258 | 19 090 | 0.009 | 2 194 250 | 0 | 0 | 39 |
| US EQ-5D tariff | 258 | 20 916 | 0.005 | 3 926 628 | 0 | 0 | 28 |
| Healthcare perspective | |||||||
| Overall (main analysis) | 258 | 16 956 | 0.009 | 1 948 919 | 0 | 0 | 41 |
| Sensitivity analysis | |||||||
| US EQ-5D tariff | 258 | 16 956 | 0.005 | 3 183 050 | 0 | 0 | 32 |
EQ-5D, EuroQol 5-Dimensions; ICER, Incremental cost-effectiveness ratio; QALY, Quality-adjusted life-year.